Korro Bio (KRRO) counsel’s mandatory share sale covers RSU tax
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Korro Bio, Inc. General Counsel Jeffrey Cerio reported an open-market sale of 6,609 shares of common stock at a weighted-average price of $10.83 per share. According to the filing, this was a mandatory sale solely to satisfy tax withholding obligations from vested restricted stock units under the 2023 equity plan.
After this transaction, Cerio holds 35,293 shares directly, including 20,951 shares underlying restricted stock units that are scheduled to vest on December 15, 2026, if his service with the company continues through that date.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 6,609 shares ($71,575)
Net Sell
1 txn
Insider
Cerio Jeffrey
Role
General Counsel
Sold
6,609 shs ($72K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 6,609 | $10.83 | $72K |
Holdings After Transaction:
Common Stock — 35,293 shares (Direct, null)
Footnotes (1)
- Represents the mandatory sale of shares of common stock solely to satisfy tax withholding obligations incurred upon vesting and settlement of a restricted stock unit (RSU) granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan). The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions at prices ranging from $10.58 to $11.35, inclusive. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission upon request. Includes 20,951 shares of common stock issuable upon settlement of a RSU granted under the 2023 Plan that will vest on December 15, 2026 subject to the reporting person maintaining a continuous Service Relationship (as defined in the 2023 Plan) through such date.
Key Figures
Shares sold: 6,609 shares
Weighted-average sale price: $10.83 per share
Post-transaction holdings: 35,293 shares
+2 more
5 metrics
Shares sold
6,609 shares
Open-market sale on 2026-06-16 to cover tax withholding
Weighted-average sale price
$10.83 per share
Common stock sale on 2026-06-16
Post-transaction holdings
35,293 shares
Common stock held directly after sale
Unvested RSUs
20,951 shares
RSUs scheduled to vest on December 15, 2026
Sale price range
$10.58–$11.35 per share
Price range of multiple sale transactions
Key Terms
restricted stock unit (RSU), weighted-average price, 2023 Stock Option and Incentive Plan, continuous Service Relationship
4 terms
restricted stock unit (RSU) financial
"Represents the mandatory sale of shares of common stock solely to satisfy tax withholding obligations incurred upon vesting and settlement of a restricted stock unit (RSU)..."
A restricted stock unit (RSU) is a promise from a company to give an employee company shares (or cash equal to their value) at a future date if certain conditions are met, such as staying with the company or hitting performance targets. For investors, RSUs matter because when they convert into actual shares they increase the number of shares available and can create selling pressure as employees cash out—think of them as a future paycheck paid in company stock.
weighted-average price financial
"The price reported in Column 4 is a weighted-average price. The shares were sold in multiple transactions..."
2023 Stock Option and Incentive Plan financial
"RSU granted under the Issuer's 2023 Stock Option and Incentive Plan (the 2023 Plan)."
continuous Service Relationship financial
"will vest on December 15, 2026 subject to the reporting person maintaining a continuous Service Relationship..."
FAQ
What insider transaction did Korro Bio (KRRO) report for Jeffrey Cerio?
Korro Bio reported that General Counsel Jeffrey Cerio sold 6,609 shares of common stock at a weighted-average price of $10.83 per share. The sale was described as mandatory to cover tax withholding obligations from vesting restricted stock units under the company’s 2023 equity plan.
Was the Korro Bio (KRRO) insider sale a discretionary trade?
The sale was described as a mandatory transaction to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units. This characterization indicates it was driven by tax requirements rather than a discretionary decision to reduce equity exposure in Korro Bio shares.
What are the terms of Jeffrey Cerio’s unvested RSUs at Korro Bio (KRRO)?
Cerio’s holdings include 20,951 shares of common stock issuable upon settlement of restricted stock units granted under the 2023 Stock Option and Incentive Plan. These RSUs are scheduled to vest on December 15, 2026, provided he maintains a continuous service relationship through that date.